{"id":7375,"date":"2012-04-23T01:26:32","date_gmt":"2012-04-23T01:26:32","guid":{"rendered":"http:\/\/cardiophile.org\/?p=7375"},"modified":"2012-04-23T01:26:32","modified_gmt":"2012-04-23T01:26:32","slug":"ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/","title":{"rendered":"Ulinastatin for reducing coronary lesions in Kawasaki disease"},"content":{"rendered":"

Ulinastatin for reducing coronary lesions in Kawasaki disease<\/span><\/h2>\n

Ulinastatin for reducing coronary lesions in Kawasaki disease: Higher plasma levels of neutrophil elastase and markedly activated neutrophils have been associated with poor response to intravenous immunoglobulin (IVIG) and coronary artery lesions in Kawasaki disease. Ulinastatin<\/strong>, a urinary trypsin inhibitor<\/em><\/strong> has been used as a suppressor of neutrophils<\/em><\/strong>. A retrospective study by Kanai T et al [1] evaluated the benefits of this drug in Kawasaki disease. They could identify 369 patients who were treated with a combination of ulinastatin, intravenous immunoglobulin and aspirin. 1178 patients who were treated with IVIG and aspirin<\/a> served as the control group. They found that those treated with ulinastatin had lower rates of coronary artery lesions (3% versus 7%; P=0.01).
\nThe drug has been tried in other conditions like pancreatitis [2], multiorgan dysfunction syndrome [3], sepsis [4] and post operative cognitive dysfunction [5]. It is considered as an immunomodulator in some of this conditions. Its anti inflammatory effects are dependent on inhibition of neutrophil derived elastase, tumour necrosis factor alpha, pro-inflammatory cytokines and interleukins. It can also suppress activation of macrophages and platelets. The medications has been approved in Japan. Clinical trials are progressing across the globe. Use in Kawasaki disease at present can be considered as an off label use.<\/p>\n

References<\/strong><\/span><\/p>\n

    \n
  1. Kanai T, Ishiwata T, Kobayashi T, Sato H, Takizawa M, Kawamura Y, Tsujimoto H, Nakatani K, Ishibashi N, Nishiyama M, Hatai Y, Asano Y, Kobayashi T, Takeshita S, Nonoyama S.\u00a0Ulinastatin, a urinary trypsin inhibitor, for the initial treatment of patients with Kawasaki disease: a retrospective study.\u00a0Circulation. 2011 Dec 20;124(25):2822-8.<\/li>\n
  2. Wang LZ, Luo MY, Zhang JS, Ge FG, Chen JL, Zheng CQ.\u00a0Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis\u2029.\u00a0Int J Clin Pharmacol Ther. 2016 Nov;54(11):890-898.<\/li>\n
  3. Atal SS, Atal S. Ulinastatin – a newer potential therapeutic option for multiple organ dysfunction syndrome.
    \nJ Basic Clin Physiol Pharmacol. 2016 Mar;27(2):91-9.<\/li>\n
  4. Feng Z, Shi Q, Fan Y, Wang Q, Yin W.\u00a0\u00a0Ulinastatin and\/or thymosin \u03b11 for severe sepsis: A systematic review and meta-analysis.\u00a0J Trauma Acute Care Surg. 2016 Feb;80(2):335-40.<\/li>\n
  5. Lv ZT, Huang JM, Zhang JM, Zhang JM, Guo JF, Chen AM.\u00a0<\/span>Effect of Ulinastatin in the Treatment of Postperative Cognitive Dysfunction: Review of Current Literature.\u00a0Biomed Res Int. 2016;2016:2571080.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Kawasaki disease patients treated with ulinastatin (urinary trypsin inhibitor – a suppressor of neutrophils) had lower rates of coronary artery lesions. <\/p>\n","protected":false},"author":1,"featured_media":39464,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-7375","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"\nUlinastatin for reducing coronary lesions in Kawasaki disease<\/title>\n<meta name=\"description\" content=\"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ulinastatin for reducing coronary lesions in Kawasaki disease\" \/>\n<meta property=\"og:description\" content=\"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2012-04-23T01:26:32+00:00\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"Ulinastatin for reducing coronary lesions in Kawasaki disease\",\"datePublished\":\"2012-04-23T01:26:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/\"},\"wordCount\":383,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/\",\"name\":\"Ulinastatin for reducing coronary lesions in Kawasaki disease\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#primaryimage\"},\"thumbnailUrl\":\"\",\"datePublished\":\"2012-04-23T01:26:32+00:00\",\"description\":\"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#primaryimage\",\"url\":\"\",\"contentUrl\":\"\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ulinastatin for reducing coronary lesions in Kawasaki disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ulinastatin for reducing coronary lesions in Kawasaki disease","description":"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/","og_locale":"en_US","og_type":"article","og_title":"Ulinastatin for reducing coronary lesions in Kawasaki disease","og_description":"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.","og_url":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2012-04-23T01:26:32+00:00","author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"Ulinastatin for reducing coronary lesions in Kawasaki disease","datePublished":"2012-04-23T01:26:32+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/"},"wordCount":383,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#primaryimage"},"thumbnailUrl":"","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/","url":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/","name":"Ulinastatin for reducing coronary lesions in Kawasaki disease","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#primaryimage"},"thumbnailUrl":"","datePublished":"2012-04-23T01:26:32+00:00","description":"Ulinastatin for reducing coronary lesions in Kawasaki disease: Ulinastatin (suppressor of neutrophils) had lower rates of coronary artery lesions.","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#primaryimage","url":"","contentUrl":""},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/ulinastatin-for-reducing-coronary-lesions-in-kawasaki-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"Ulinastatin for reducing coronary lesions in Kawasaki disease"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7375","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=7375"}],"version-history":[{"count":0,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/7375\/revisions"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=7375"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=7375"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=7375"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}